Provenge is indicated for men with asymptomatic or minimally symptomatic mCRPC. It is particularly considered for patients whose cancer has progressed despite androgen deprivation therapy (ADT). However, it is not suitable for all prostate cancer patients, and eligibility must be determined by a healthcare provider based on specific clinical criteria.
